Of particular interest would be longitudinal investigations to assess whether upregulation of anti-inflammatory genes (e.g. Trem2 and Tgfb1) becomes superseded by pro-inflammatory markers, and how this relates to the timecourse of metabolic pathology in the TgF344-AD model. This evidence concerns the gene TREM2 and Alzheimer disease.